Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2012 - 2026)

Enanta Pharmaceuticals' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$7.3 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 5.92% year-over-year to -$7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.1 million (up 263.57% YoY) and the FY2025 annual result came in at -$26.6 million, up 3.65% from the prior year.
• Cash from Financing Activities was -$7.3 million for Q1 2026 at Enanta Pharmaceuticals, down from $64.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $199.9 million in Q2 2023 and bottomed at -$8.3 million in Q3 2025.
• A 5-year average of $12.4 million and a median of -$5.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 4751.33% — and 2024, when it slumped 31269.57%.
• Enanta Pharmaceuticals' Cash from Financing Activities stood at $301000.0 in 2022, then sank by 2541.86% to -$7.4 million in 2023, then soared by 32.16% to -$5.0 million in 2024, then surged by 1386.32% to $64.1 million in 2025, then sank by 111.37% to -$7.3 million in 2026.
• Business Quant data shows ENTA's Cash from Financing Activities at -$7.3 million in Q1 2026, $64.1 million in Q4 2025, and -$8.3 million in Q3 2025.